Loading patent…
AssigneeNovartis AG
InventorsPaul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
Estimating the term…
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
An isolated nucleic acid comprising a nucleic acid sequence having at least 75% sequence identity to:
An isolated polypeptide comprising an amino acid sequence having at least 75% sequence identity to:
An isolated Seneca Valley virus or derivative thereof, comprising identifying characteristics of ATCC Patent Deposit number PTA-5343.
An isolated Seneca Valley virus or derivative or relative thereof, having a genome comprising a sequence that is at least 95%, 90%, 85%, 80%, 75%, 70%, or 65% identical to SEQ ID NO:1 or SEQ ID NO:168.
A method for treating cancer comprising administering an effective amount of a virus or derivative thereof, so as to treat the cancer, wherein the virus has a genome that comprises a sequence that is at least 75% identical to a contiguous sequence of SEQ ID NO:1 or SEQ ID NO:168 that is at least 100 nucleotides in length.
A method for making an oncolytic virus, the method comprising:
Dependencies are inferred from the claim text.